Integral Health Asset Management LLC Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Integral Health Asset Management LLC lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 125.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 450,000 shares of the company's stock after acquiring an additional 250,000 shares during the period. Integral Health Asset Management LLC owned approximately 1.11% of Keros Therapeutics worth $7,124,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Deutsche Bank AG increased its position in shares of Keros Therapeutics by 45.6% during the fourth quarter. Deutsche Bank AG now owns 26,957 shares of the company's stock valued at $427,000 after acquiring an additional 8,447 shares in the last quarter. DAFNA Capital Management LLC increased its position in shares of Keros Therapeutics by 76.7% during the fourth quarter. DAFNA Capital Management LLC now owns 130,316 shares of the company's stock valued at $2,063,000 after acquiring an additional 56,562 shares in the last quarter. Braidwell LP increased its position in shares of Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Brevan Howard Capital Management LP increased its position in shares of Keros Therapeutics by 95.6% during the fourth quarter. Brevan Howard Capital Management LP now owns 11,186 shares of the company's stock valued at $177,000 after acquiring an additional 5,468 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Keros Therapeutics during the fourth quarter valued at approximately $730,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock traded up $0.04 on Friday, hitting $14.07. 633,971 shares of the company's stock were exchanged, compared to its average volume of 835,944. The company has a 50-day simple moving average of $12.43 and a 200-day simple moving average of $22.86. The stock has a market capitalization of $571.45 million, a PE ratio of -2.70 and a beta of 1.32. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter last year, the company posted ($1.21) EPS. On average, analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 22.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KROS. HC Wainwright reduced their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Scotiabank cut their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Finally, Piper Sandler cut their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.